Genomes and Genes


Eduardo Castañón


Affiliation: University of Navarra
Country: Spain


  1. Baraibar I, Melero I, Ponz Sarvisé M, Castañon E. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf. 2019;: pubmed publisher
    ..This review focuses on the mechanisms of toxicity of anti-PD-1/PD-L1 agents, and its diagnosis and management. ..
  2. Van Der Steen N, Pauwels P, Gil Bazo I, Castañon E, Raez L, Cappuzzo F, et al. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers (Basel). 2015;7:556-73 pubmed publisher
    ..We will also look into aberrations in the signaling and the effects thereof in cancer growth, with the focus on NSCLC. Finally, we will discuss the role of cMET as resistance mechanism. ..
  3. Castañón E, Rolfo C, Viñal D, López I, Fusco J, Santisteban M, et al. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. J Transl Med. 2015;13:257 pubmed publisher
    ..81). Overall, liver metastases at onset negatively impact OS of NSCLC patients. EGFR TKIs however, may reverse the effects of an initial negative prognosis of liver metastasis in first-line treatment of EGFR mutated NSCLC patients. ..